US · Healthcare · Biotechnology
EPS came in at -0.50 against a street estimate of -0.14 — a miss of 257.1%.
Analysts rate Alpha Tau Medical Ltd a buy (4 buy, 1 hold, 0 sell out of 5) with an average price target of $17.80.
| Fund | Stake |
|---|---|
| Gem Investment Advisors, LLC | 1.55% |
| HighTower Advisors, LLC | 0.95% |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.84% |
| Aquamarine Financial (Cayman) Ltd | 0.78% |
| Pier Capital, LLC | 0.75% |
| UBS Group AG | 0.69% |
| Apella Capital, LLC | 0.41% |
| ARK Investment Management LLC | 0.30% |
| Document | Date |
|---|---|
| Report of foreign private issuer (6-K) · Q3 2026 HEADLINE NUMBERS • Alpha Tau Medical announced on August 31, 2026 that it completed patient enrollment in its multicenter IMPACT pancreatic cancer pi | 2026-08-31 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Unaudited six-month results ended June 30, 2026; all figures are in U.S. dollars in thousands unless stated otherwise. • Net los | 2026-08-10 |
| Report of foreign private issuer (6-K) · Q3 2026 OTHER NOTABLE POINTS • Alpha Tau Medical Ltd. announced on August 10, 2026, that it has registered for a dual listing on the Tel Aviv Stock Exchange | 2026-08-10 |
| Report of foreign private issuer (6-K) · Q3 2026 HEADLINE NUMBERS • Alpha Tau reported positive results for Alpha DaRT combined with pembrolizumab in elderly patients with recurrent, unresectable or | 2026-07-21 |
| Annual report FY2025 (20-F) HEADLINE NUMBERS • Fiscal year covered: year ended December 31, 2025. • Ordinary shares outstanding as of December 31, 2025: 88,009,737. • Net loss | 2026-03-09 |
| Annual report FY2024 (20-F) | 2025-03-12 |
| Annual report FY2023 (20-F) | 2024-03-07 |
| Annual report FY2022 (20-F) | 2023-03-09 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Alpha Tau Medical Ltd — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.